(Reuters) – GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.
The British drugmaker expects 2024 vaccine sales to decrease by low-single digit percentage in turnover. It previously expected the business to grow by a low to mid-single digit percentage.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Rashmi Aich)
